Thursday, 15 October 2026European Markets
Via News Knowledge File

Intel Corporation

organization80% conf.·synced Oct 15, 2026

CPU competitor to AMD

60
sourced metrics
1172
relationships
20
stated objectives
8
Via News reports

Every fact below is drawn from Via News's knowledge graph and linked to the source document it came from. Nothing here is unsourced. How we source →

Key metrics · each point sourced

Price 52 Week High
140.94USD
Oct 14, 2026reference only
Price 52 Week Low
33.62USD
Oct 14, 2026reference only
Stock Price
98.12USD
Oct 14, 2026reference only
Market Cap
494917280000USD
Oct 14, 2026reference only
Stock Return Ytd
149.2%
Oct 14, 2026reference only
Shares Outstanding
5044000000.0shares
Jul 17, 2026reference only
Rd Expense
3368000000.0USD
Jun 27, 2026reference only
Net Income
-11033000000.0USD
Jun 27, 2026reference only
Gross Profit
6509000000.0USD
Jun 27, 2026reference only
Cash
12874000000.0USD
Jun 27, 2026reference only
Revenue
16128000000.0USD
Jun 27, 2026reference only
Operating Income
1796000000.0USD
Jun 27, 2026reference only
Eps
-2.16USD_per_share
Jun 27, 2026reference only
Stockholders Equity
87542000000.0USD
Jun 27, 2026reference only
Total Assets
202439000000.0USD
Jun 27, 2026reference only
Cost Of Revenue
9619000000.0USD
Jun 27, 2026reference only
Operating Cash Flow
1096000000.0USD
Mar 28, 2026reference only
Capex
3636000000.0USD
Mar 28, 2026reference only

Stated objectives

Reduce OpEx to $16B for full year 2026

source
target: 16 billion USD by 2026-12-31 00:00:00stated

Achieve positive adjusted free cash flow for full year 2026

source
target: positive by 2026-12-31 00:00:00stated

Achieve 7-8% per month yield improvements focusing on variation, consistency, defect density

source
target: 7-8% monthly by 2026-01-01 00:00:00stated

Secure firm customer commitments for Intel 14A manufacturing

source
by 2027-06-30 00:00:00stated

Begin Intel 14A risk production

source
by 2027-12-31 00:00:00stated

Begin Intel 14A volume production

source
by 2028-01-01 00:00:00stated

Launch Nova Lake client processor

source
by 2026-12-31 00:00:00stated

Begin advanced packaging customer ramps

source
by 2026-09-30 00:00:00stated

Improve supply constraints each quarter through 2026 starting Q2

source
target: above seasonal growth by 2026-12-31 00:00:00stated

Q1 2026 revenue guidance

source
target: 11.7-12.7 billion USD by 2026-03-31 00:00:00stated

Relationship graph · 1172 connections

Competes with
307
Supplies to
192
Developed by
167
Covered by
95
Customer of
73
Employs
67
Invested in
49
subsidiary of
41

Via News coverage

This Knowledge File is assembled from Via News's source-traceable knowledge graph. Metrics, objectives and relationships are extracted from primary and credible secondary documents and refreshed on a schedule. Read our methodology →
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com